Table 1
Clinical characteristics (N = 253)
| Characteristic | PDS (N = 38) | NACT (N = 215) | P value |
|---|---|---|---|
| Age-years | |||
| Median | 53.7 | 62.2 | < 0.001 |
| Range | 29–84 | 39–85 | |
| BMI-kg/m2 | |||
| Median | 24.5 | 23.8 | 0.210 |
| Range | 17.4–45.2 | 18.2–32.1 | |
| Parity-number | |||
| Median | 2 | 2 | 0.080 |
| Range | 0–5 | 0–4 | |
| Menopause-years | |||
| Median | 50 | 51.5 | 0.340 |
| Range | 37–60 | 45–58 | |
| ASA score | |||
| 1 | 7 (18.4) | 23 (10.7) | 0.780 |
| 2 | 22 (57.9) | 141 (65.6) | |
| 3 | 9 (23.7) | 49 (22.8) | |
| 4 | 0 (0) | 2 (0.9) | |
| WHO performance status | |||
| 0 | 26 (68.4) | 96 (44.7) | 0.130 |
| 1 | 8 (21.0) | 85 (40.0) | |
| 2 | 4 (10.6) | 26 (12.1) | |
| 3 | 0 (0) | 5 (2.3) | |
| 4 | 0 (0) | 3 (1.4) | |
| FIGO stage | |||
| IIIC | 34 (89.5) | 143 (66.6) | 0.010 |
| IV | 4 (10.5) | 72 (33.4) | |
| Histologic type | |||
| Serous | 32 (84.2) | 202 (94.0) | 0.100 |
| Endometrioid | 6 (15.8) | 8 (3.7) | |
| Mucinous | 0 (0) | 3 (1.4) | |
| Clear-cell | 0 (0) | 2 (0.9) | |
| Preoperative CA-125– IU/ml | |||
| Median | 499 | 972 | 0.058 |
| Range | 59–5739 | 10–31481 | |
| Surgical outcome | |||
| Complete gross resection | 9 (23.7) | 124 (57.6) | 0.002 |
| Optimal visible residual (≤1 cm) | 7 (18.4) | 30 (14.0) | |
| Suboptimal (>1 cm) | 22 (57.9) | 61 (28.4) | |
| Hospitalisation time-days | |||
| Median | 10 | 9 | 0.555 |
| Range | 7–28 | 5–59 |
Table 2
Median and range CA-125 levels in different surgical outcomes in primary debulking surgery (PDS) and = neoadjuvant chemotherapy (NACT) group
| Surgical outcomes | PDS (N = 38) | NACT (N = 215) | P value |
|---|---|---|---|
| CA-125 at diagnosis IU/ml | |||
| Complete gross resection | 359 59–5739 | 943 10–12803 | 0.006 |
| Optimal resection | 512 85–1117 | 1006 48–24824 | |
| Suboptimal resection | 1522 200–3569 | 1063 28–31481 | |
| CA-125 post NACT IU/ml | |||
| Complete gross resection | 25 5–2074 | 0.020 | |
| Optimal resection | 36 15–2180 | ||
| Suboptimal resection | 68 9–2657 |